Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
Agenus Inc. (Nasdaq: AGEN), a leading developer of novel immunological agents for cancer treatment, has announced its plans to release second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and provide a corporate update. Interested parties can register for the conference call, which has the Conference ID: 73242. A live webcast and replay of the call will be available on the company's investor relations website.
Agenus Inc. (Nasdaq: AGEN), un importante sviluppatore di nuovi agenti immunologici per il trattamento del cancro, ha annunciato i suoi piani per rilasciare i risultati finanziari del secondo trimestre 2024 il giovedì 8 agosto 2024, prima dell'apertura del mercato. L'azienda condurrà una conferenza telefonica e una webcast alle 8:30 a.m. ET dello stesso giorno per discutere i risultati e fornire un aggiornamento aziendale. Le parti interessate possono registrarsi per la conferenza telefonica, che ha l'ID Conferenza: 73242. Una webcast in diretta e la registrazione della chiamata saranno disponibili sul sito web delle relazioni con gli investitori dell'azienda.
Agenus Inc. (Nasdaq: AGEN), un desarrollador líder de nuevos agentes inmunológicos para el tratamiento del cáncer, ha anunciado sus planes para publicar los resultados financieros del segundo trimestre de 2024 el jueves 8 de agosto de 2024, antes de la apertura del mercado. La empresa realizará una llamada de conferencia y una transmisión por web a las 8:30 a.m. ET del mismo día para discutir los resultados y proporcionar una actualización corporativa. Las partes interesadas pueden registrarse para la llamada de conferencia, que tiene el ID de Conferencia: 73242. Una transmisión en vivo y una repetición de la llamada estarán disponibles en el sitio web de relaciones con inversores de la empresa.
Agenus Inc. (Nasdaq: AGEN)는 암 치료를 위한 새로운 면역학적 제제의 주요 개발자로서 2024년 2분기 재무 결과를 2024년 8월 8일 목요일, 시장 개장 전에 발표할 계획을 발표했습니다. 회사는 같은 날 오전 8시 30분 ET에 결과를 논의하고 기업 업데이트를 제공하기 위한 컨퍼런스 콜 및 웹캐스트를 진행합니다. 관심 있는 분들은 회의 ID가 73242인 컨퍼런스 콜에 등록할 수 있습니다. 회사의 투자자 관계 웹사이트에서는 라이브 웹캐스트와 콜의 재녹화가 제공될 예정입니다.
Agenus Inc. (Nasdaq: AGEN), un leader dans le développement de nouveaux agents immunologiques pour le traitement du cancer, a annoncé son intention de publier les résultats financiers du deuxième trimestre 2024 le jeudi 8 août 2024, avant l'ouverture du marché. L'entreprise organisera un appel conférence et un webinaire le même jour à 8h30 ET pour discuter des résultats et fournir une mise à jour sur l'entreprise. Les parties intéressées peuvent s'inscrire à l'appel conférence, qui a l'ID de conférence : 73242. Un webinaire en direct et un replay de l'appel seront disponibles sur le site Web des relations investisseurs de l'entreprise.
Agenus Inc. (Nasdaq: AGEN), ein führender Entwickler neuartiger immunologischer Mittel zur Krebsbehandlung, hat seine Pläne angekündigt, die Finanzergebnisse für das zweite Quartal 2024 am Donnerstag, den 8. August 2024, vor Markteröffnung zu veröffentlichen. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und ein Webcast abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate bereitzustellen. Interessierte können sich für die Telefonkonferenz registrieren, die die Konferenz-ID: 73242 hat. Ein Live-Webcast sowie eine Wiederholung der Konferenz werden auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
Conference Call:
To access dial-in numbers, please register here.
Conference ID: 73242
A live webcast and replay of the conference call will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding a its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2022, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240726475067/en/
Investors
917-362-1370
investor@agenusbio.com
Media
612-839-6748
communications@agenusbio.com
Source: Agenus Inc.
FAQ
When will Agenus (AGEN) release its Q2 2024 financial results?
What time is Agenus (AGEN) hosting its Q2 2024 earnings call?
How can I access Agenus (AGEN) Q2 2024 earnings call?
What is the Conference ID for Agenus (AGEN) Q2 2024 earnings call?
